As a new type of foreign trade service provider driven by both technological transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from well-known original manufacturers of polygonum cuspidatum extract. As a foreign trade service provider with R&D capabilities, HiSiaddi has repeatedly resolved customized product demands for polygonum cuspidatum extract for clients through technological transformation cooperation with factories and accurate insight into market demands. The following is a case of HiSiaddi addressing customized demands for polygonum cuspidatum extract products.
For more customized service inquiries, please contact HiSiaddi customer service.
The purchaser is NutraPharma, a high-end nutritional pharmaceutical group based in California, USA. With over 20 years of R&D and production experience in prescription drug excipients, premium dietary supplements and hospital-grade antioxidant formulations across North America, its products are sold at premium organic supermarket chain Whole Foods, private hospital pharmacies across the U.S., and included in the designated procurement catalog of the North American Sports Physicians Alliance. All its products comply with six stringent access standards: USP-NF United States Pharmacopeia-National Formulary, FDA GRAS raw material certification, California Proposition 65, EPA pesticide residue control, NON-GMO verification, and Kosher kosher certification. Its two flagship product lines are cardiovascular support capsules and high-purity antioxidant oral liquids, for which customized polygonum cuspidatum extract serves as the core raw material for high-end sustained-release tablet formulations. The group has long sourced customized polygonum cuspidatum extract from leading raw material enterprises in Europe and America, representing a typical mid-to-high-end buyer focused on refined customized procurement that refuses generic bulk extracts and low-cost non-standard raw materials circulating on the market.
Driven by surging production costs of native plant extracts in Europe and America and extended customization lead times of over 3 months at major manufacturers, the client’s procurement and R&D departments launched a localized Chinese customized raw material procurement project. The client independently screened three large-scale domestic plant extract manufacturers to discuss customized polygonum cuspidatum extract requirements. Its rigid customized indicators differ significantly from conventional resveratrol extracts available on the market: a compound ratio of trans-resveratrol ≥10% + polydatin ≥30%, emodin controlled below 0.3%, ethanol residual solvent <500ppm, pesticide residues compliant with EU Regulation EC396, heavy metals (lead, arsenic, cadmium, mercury) within USP limits, powder repose angle of 38°±2 for smooth sustained-release tableting, zero synthetic chemical additives, and fully traceable organic polygonum cuspidatum planting bases for raw materials.
However, all three domestic plant extract manufacturers primarily mass-produce standardized finished products, with mainstream stock of conventional single-ingredient specifications: 5%, 20% and 98% resveratrol. They only produce fixed-ratio products based on mature in-house processes and are unwilling to reconstruct extraction, chromatography and crystallization production lines for niche compound formulations. Most factories adopt traditional ethanol reflux and ambient-temperature concentration processes, which cannot precisely synchronize the content control of polydatin and trans-resveratrol. After 42 rounds of small-batch trials, all samples failed to meet standards: either polydatin content fell below 22%, or emodin exceeded 0.8%, failing to satisfy the production requirements for sustained-release tablets. The client’s R&D testing expenses exceeded USD 17,000, and the scheduled new product launch was delayed by 75 days. All three factories stated their existing production lines could not support personalized compound customization and were unable to deliver the non-standard indicators requested by the client. Recommended by industry peers, the client fully entrusted HiSiaddi, a foreign trade technical service provider specializing in plant extracts, to deliver end-to-end customized production relying on China’s industrial chain resources, resolving all customization challenges covering raw material sourcing, process modification, pilot verification, compliance testing and export filing.
After collecting the client’s customized standards, test reports of unqualified samples and formulation documents for American finished products, HiSiaddi’s technical team sorted out five key pain points that conventional domestic plant extract enterprises struggle to resolve for high-end customization, which also constituted the technical hurdles to be overcome in this project.
Most domestic factories purchase wild-harvested polygonum cuspidatum rhizomes in bulk, with inconsistent harvesting seasons and varying plant maturity. Rhizome epidermis and xylem are mixed as feedstock: trans-resveratrol accumulates in the epidermis while polydatin distributes in phloem. Mixed feeding causes natural component fluctuations exceeding ±4%, making it impossible to stably lock the precise ratio of 10% trans-resveratrol and 30% polydatin. Meanwhile, bulk wild-sourced raw materials cannot provide GAP organic planting traceability ledgers required by the U.S., violating FDA raw material filing specifications.
Generic market processes adopt high-temperature single ethanol reflux extraction. Under high temperatures, polydatin easily hydrolyzes into trans-resveratrol, causing severe polydatin loss. Increasing polydatin content inevitably reduces trans-resveratrol levels, making synchronous quantitative control unachievable. Conventional resin chromatography only enriches trans-resveratrol alone, lacking segmented separation and purification procedures or customized gradient elution schemes for dual components. It is impossible to precisely remove natural emodin impurities down to below 0.3%.
Standard high-temperature hot air drying causes caking and uneven particle size of extracts, with a universal repose angle over 48% and extremely poor flowability. The client’s automatic tableting equipment suffers material bridging and blockages at feed ports, leading to excessive tablet weight deviation. High-temperature drying also triggers degradation of partial active ingredients: finished products darken and lose potency after 3 months of storage, failing to meet the 24-month shelf life stability requirement for high-end North American formulations.
Small and medium plant extract manufacturers employ crude ethanol recovery processes without refined parameter control for solvent removal, resulting in universal ethanol residual levels above 1200ppm, far exceeding the client’s rigid limit of <500ppm. Raw materials lack standardized pre-screening for pesticide residues, with batches testing positive for excessive organophosphorus and pyrethroid pesticides, risking failure in FDA entry inspections at U.S. customs.
Domestic factories only provide domestic standard factory self-inspection reports, lacking CNAS third-party full COAs, complete pesticide residue screening reports, organic traceability documents, and English SDS safety data sheets formatted for FDA standards. Even if sample indicators pass inspection, finished products cannot be filed with U.S. drug authorities or sold in pharmacies.
HiSiaddi set up a special project team consisting of plant extract process engineers, U.S. regulatory compliance specialists and third-party testing coordinators. It selected two mid-to-high-end plant extract manufacturers in China with flexible customized production lines and cooperative GAP organic planting bases, implementing customized production in five sequential steps: source raw material control, customized extraction and purification processes, powder physical modification, multiple rounds of small and pilot trials, and full compliance supporting documents. Verification was conducted in three progressive batches: 50g lab samples, 50kg pilot batches, and 3.2-ton mass production runs.
HiSiaddi partnered with contracted standardized GAP polygonum cuspidatum planting bases in western Hunan. Harvesting is restricted to mature 3-year-old rhizomes between October and November annually. Rhizome epidermis and phloem are manually sorted separately, with woody core materials discarded. Standardized workflows are fixed for harvesting, cleaning and shade drying, with harvesting ledgers and pesticide application records attached to every raw material batch to achieve full traceability from field to finished extract. This minimizes natural component fluctuations from the source, laying a foundation for subsequent precise ratio control.
The traditional high-temperature full reflux process was discarded in favor of segmented low-temperature enzymatic hydrolysis and graded ethanol percolation extraction. Cell walls are broken down via low-temperature biological enzymes, followed by 45°C segmented low-temperature percolation with two separate collections of extraction liquid to avoid polydatin hydrolysis under high heat. Two macroporous resins with differing polarity are connected in series for chromatography: the first enriches polydatin, and the second targets trans-resveratrol enrichment. An additional alumina micro anthraquinone removal stage precisely strips free emodin. After multiple rounds of parameter fine-tuning, stable target ranges were achieved: trans-resveratrol 10.1%–10.5%, polydatin 30.2%–30.8%, emodin 0.22%–0.28%, fully within the client’s required indicator window.
Hot air drying was replaced with vacuum low-temperature freeze drying to maximize active ingredient stability. Post-lyophilization jet milling and closed screening adjust particle size distribution, delivering finished powder with a stable repose angle of 36°–39%. The loose, non-hygroscopic powder supports continuous feeding on the client’s automatic sustained-release tableting equipment. Accelerated stability testing confirmed active ingredient degradation below 2% over 24 months, meeting North America’s long-term shelf storage standards.
Factory ethanol rectification recovery systems were upgraded with three-stage negative-pressure low-temperature desolventization, stabilizing ethanol residual levels ≤320ppm. All incoming raw material batches undergo pre-testing for over 200 restricted pesticides under European and American standards at CNAS-accredited laboratories; batches failing screening are rejected outright. Heavy metal levels in finished products outperform USP pharmacopoeia control limits, eliminating customs inspection risks.
HiSiaddi coordinated third-party laboratories to issue bilingual batch-bound COAs covering all indicators: active ingredients, pesticide residues, heavy metals and residual solvents. English SDS safety data sheets were drafted in alignment with California Proposition 65 and FDA regulations, alongside complete organic traceability archives and Kosher certification copies. The team assisted the client with pre-approval filing of raw materials with the U.S. FDA, delivering a full set of documents directly usable for finished product drug administration filing and supermarket shelf listing applications.
After six rounds of cross-border sample shipments and full physicochemical and formulation pilot verification at the client’s U.S. R&D laboratory, all indicators of the customized polygonum cuspidatum extract passed inspection. The first 3.2 tons of customized product were shipped via thermostatically controlled moisture-proof packaging to bonded warehouses in Los Angeles. Post-implementation, the client’s sustained-release tablet production line operated stably for 25 consecutive days without feed blockages or excessive tablet weight deviation. Finished tablet qualification rates rose from 72% using generic raw materials to 99.3%, enabling the delayed premium new product to launch across all Whole Foods retail channels nationwide.
The client immediately finalized a long-term framework procurement order for 18.5 tons annually, split into 11 monthly batches. Subsequent demand emerged for subdivided customized low-irritation cosmetic-grade polygonum cuspidatum extract, with HiSiaddi fully overseeing full-spectrum customized R&D, production control and compliance paperwork for all product categories. Compared with the client’s original European and American imported customized raw materials, localized Chinese procurement delivered a 31.2% reduction in comprehensive costs and cut delivery lead times from 48 days to 26 days, significantly optimizing the client’s global raw material supply chain cost structure.
Leveraging the stabilized customized raw material system, NutraPharma expanded its market footprint into premium pharmaceutical and nutritional sectors in Canada and Australia, launching new customized polygonum cuspidatum extract lines for high-end pet antioxidant formulations. HiSiaddi continued iterative process optimization in coordination with domestic factories, fine-tuning product indicators to align with regional regulatory standards including Australia’s TGA and Canada’s NPN. Endorsed by this fixed-supply partnership with a top-tier U.S. pharmaceutical enterprise, the two cooperating plant extract manufacturers upgraded flexible customized production lines and secured long-term customized orders from four equivalent high-end nutritional brands in Canada and Australia. This allowed manufacturers to shift away from low-price homogenized competition centered on mass generic raw materials and transform into high-end customized raw material suppliers. Building on this project, HiSiaddi refined a multi-specification customized process database for polygonum cuspidatum extract and established standardized end-to-end service workflows covering raw material cultivation, customized processing, compliance testing and cross-border delivery, continuing to accept customized plant extract projects for mid-to-high-end pharmaceutical and dietary brands worldwide.
The vast majority of domestic plant extract manufacturers focus on mass production of standardized generic finished goods, with production lines, processes and quality control designed around mainstream commercial specifications. R&D investment prioritizes mass-production cost reduction, lacking R&D capacity for non-standard customization demanded by overseas high-end pharmaceutical enterprises, alongside insufficient familiarity with European and American pharmacopoeias, food regulations and finished formulation production conditions. While overseas mid-to-high-end pharmaceutical and nutritional brands excel in end-product formulation R&D and possess thorough knowledge of domestic drug administration standards and manufacturing details, they lack understanding of process limitations and raw material resources within China’s plant extract industry. Independent direct procurement frequently results in failed customization, wasted testing samples and delayed new product launches with substantial financial losses.
Breaking the traditional foreign trade model limited to spot commodity intermediary sales, HiSiaddi operates as a technology-driven foreign trade service provider. Drawing on upstream cultivation resources, midstream factory flexible modification capacity and downstream compliance testing resources, it connects the full-service chain of raw material traceability, targeted process customization, powder modification, compliance filing and cross-border delivery, bridging the technical gap between overseas clients’ high-end customization demands and domestic manufacturers’ mass-production systems. It acts as a critical link enabling domestic plant extracts to escape low-price homogenized competition and penetrate mid-to-high-end global pharmaceutical raw material supply chains.
For more customized service inquiries, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
